Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment and energy depletion

Area of Science:

• Cardiovascular Biology
• Mitochondrial Medicine
• Endocrinology

Background:

• Hyperthyroidism is associated with cardiac dysfunction.
• Metabolic remodeling plays a key role in the development of heart disease.
• Mitochondrial integrity is crucial for cardiac energy metabolism.

Purpose of the Study:

• To investigate the role of metabolic remodeling in hyperthyroidism-induced cardiac dysfunction.
• To examine the protective effects of bezafibrate (Bzf) on cardiac structure and function in a rat model of hyperthyroidism.
• To elucidate the impact of hyperthyroidism on mitochondrial function and energy metabolism.

Main Methods:

• Rats were treated with triiodothyronine (T3) to induce hyperthyroidism, with or without co-administration of bezafibrate (Bzf).
• Cardiac hypertrophy, gene expression, mitochondrial ultrastructure, oxidative stress, and heart function were assessed.
• Measurements included cytochrome c oxidase activity and myocardial ATP concentration.

Main Results:

• T3 treatment led to cardiac hypertrophy, mitochondrial damage, oxidative stress, and impaired heart function.
• Co-administration of Bzf ameliorated these T3-induced changes, improving cardiac structure, mitochondrial integrity, and function.
• Bzf treatment prevented the reduction in cytochrome c oxidase activity and ATP concentration caused by T3.

Conclusions:

• Hyperthyroidism causes significant structural and functional damage to cardiac mitochondria, leading to energy depletion and cardiac dysfunction.
• Bezafibrate (Bzf) exerts protective effects against hyperthyroidism-induced cardiac damage by preserving mitochondrial integrity and metabolic function.
• Targeting metabolic remodeling pathways may be a viable strategy for managing hyperthyroidism-related heart disease.